Posters

Real life experience of intravitreal ranibizumab therapy for wet age related macular degeneration

Poster Details

First Author: N.Kir TURKEY

Co Author(s):    Z. Cebeci   Y. Yilmaz                          

Abstract Details



Purpose:

To evaluate the real life experience and clinical results of intravitreal ranibizumab injection in wet type age-related macular degeneration (wAMD).

Setting:

Department of Ophthalmology, Istanbul Faculty of Medicine, Istanbul University, Istanbul

Methods:

101 eyes of 89 patients treated with intravitreal ranibizumab injection for wAMD that were followed up for at least 24 months between 2009 and June 2014 in Istanbul University, Faculty of Medicine , Ophthalmology Department were evaluated retrospectively. Visual acuity, central macular thickness, existence of pigment epitel detachment and intraretinal and subretinal fluid in optical coherence tomography were recorded at 3,6,12,18 and 24 months respectively. Pro Re Nata (PRN) treatment protocol was performed after 3 monthly loading injections.

Results:

34 patients were male (38,2 %) and mean age was 74.0±9,5 (52-91) years. The mean follow-up period was 24.82 (24-29) months. Mean number of visits was 8,4±1,12 (7-12) in first and 6,6 ±1,33 (4-12) in the second year. Mean number of injections was 5,8 ±1,6 (3-10), and 4,2 ±2,2 (0-9) in the first, second year, respectively. Visual acuity improved in 90 eyes at month 3, in 76 eyes at month 12 and in 74 eyes at month 24. The mean best corrected visual acuity (BCVA) was 59±15,8 ETDRS letters before treatment. The mean BCVA at 3, 12, and 24 months was found 70,3±15,9, 67,9±14,3,and 67,3±16,9 letters, respectively. Improvement in visual acuity for each visits from baseline was found statistically significant (p<0,01). We could not observed any change in visual acuity in 9 eyes at month 3, 7 eyes at month 12 and 13 eyes at month 24. The mean central macular thickness (CMT) was 437,99±164,78 µm initially. And mean CMT was 348,05 ±138,47 µm, 349,24±139,79 µm, and 344,13±146,309 µm at months 3,12 and 24, respectively . Decrease in CMT for each visit from baseline was found statistically significant (p<0,01).

Conclusions:

Anatomical and functional success was obtained in our study but the mean number of injections and visits was found to be lower than the randomized controlled clinical trials. On the other hand, the mean number of injections and visits in our study was found compatible with real life experience studies in the literature.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email: euretina@euretina.org

Privacy policyHotel Terms and Conditions Cancellation policy